Product information and disease descriptionPlace of product in therapyApproaches to treatmentCurrent treatment options and standard of care
B-cell depleting antibodies
5 evidence topics · 5 sources
Rituximab in MuSK and refractory AChR antibody-positive disease: 2020 consensus update
“A phase II RCT of RTX (Beat-MG) enrolled 52 patients with generalized nonthymomatous AChR-Ab+ MG on a stable regimen of prednisone for 4 weeks or prednisone plus another IS agent for 6 months. 27 Two cycles of RTX 6 months apart were compared to placebo with the primary outcome being a steroid-sparing effect (≥75% reduction in mean daily prednisone requirements in the 4 weeks before week 52 compared with the 4-week period before randomization). The study was designed to assess futility (nonsuperiority). Preliminary results reported that the area under the curve for prednisone was not significantly different between RTX and placebo groups, with 60% on RTX and 56% on placebo achieving the primary outcome.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Rituximab should be considered as an early therapeutic option in patients with MuSK-Ab+ MG who have an unsatisfactory response to initial immunotherapy (median 9, range 4–9). The efficacy of RTX in refractory AChR-Ab+ MG is uncertain. It is an option if patients fail or do not tolerate other IS agents (median 8, range 4–9)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Rituximab as a first-line option in new-onset disease: Nordic guidance
“In RINOMAX, 47 Swedish patients with new‐onset generalized MG (96% AChR‐antibody MG) were randomized to receive 500 mg rituximab or placebo as an add‐on to the standard of care. [ 43 ] Minimal disease manifestations at 16 weeks, defined as a Quantitative Myasthenia Gravis (QMG) score of 4 or less with a prednisolone dose ≤10 mg and no rescue treatment, was the primary endpoint. This was met by 71% in the active arm and 29% in the placebo group ( p = 0.007).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Rituximab should be considered a first‐line immunosuppressive drug in newly onset disease, as an alternative to steroids and azathioprine. Rituximab should be considered for treatment‐refractory symptoms, although evidence for its effectiveness is weaker than in newly onset disease.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Early rituximab: British guideline update
“Randomised controlled trial evidence now supports early use of rituximab (within 1 year of generalised disease onset), although the evidence is less robust, but still likely to be useful, in established treatment-refractory MG.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Systematic review of rituximab in myasthenia gravis
“We included two RCTs with a total of 99 participants.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Rituximab's effects on symptom severity and functional ability in the long‐term are uncertain. The evidence suggests that rituximab results in little to no difference in its steroid‐sparing effect; however, it probably results in a large reduction in relapse requiring rescue therapy over nine months, based on results from two studies.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote